Cochrane Review Group

Hypertension

56 systematic reviews in Hypertension ask 535 questions. 6.9% have no studies to answer them, 17% rest on very low certainty evidence and 39.6% reach moderate or high certainty.

Reviews

Questions

535

current versions

No studies

6.9%

Moderate or high

39.6%

No studies 37 · 6.9%Ungraded 34 · 6.4%Very low 91 · 17%Low 161 · 30.1%Moderate 136 · 25.4%High 76 · 14.2%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Hypertension

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Evening vs morning dosing regimen All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 0.49 [0.04, 5.42]	1 study · 735 participants	Very low
Evening vs morning dosing regimen Cardiovascular mortality (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	no estimate extracted	NR	No studies
Evening vs morning dosing regimen Cardiovascular morbidity (stroke, myocardial infarction, congestive heart failure, aortic aneurysm) (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	no estimate extracted	NR	No studies
Evening vs morning dosing regimen Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 1.17 [0.53, 2.57]	2 studies · 833 participants	Very low
Evening vs morning dosing regimen Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 0.89 [0.67, 1.2]	7 studies · 1541 participants	Very low
Evening vs morning dosing regimen Withdrawals from treatment due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 0.76 [0.47, 1.23]	7 studies · 1777 participants	Very low
First‐line thiazides vs first‐line ACE inhibitors Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane	no estimate extracted	NR	No studies
First‐line thiazides vs first‐line beta‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane	no estimate extracted	NR	No studies
First‐line thiazides vs first‐line alpha‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Pravastatin 10 to 80 mg/day (6 to 156 weeks) · participants with normal or abnormal lipid profiles Pravastatin for lowering lipids (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR WDAEs · participants with normal or abnormal lipid profiles Pravastatin for lowering lipids (2023) · Cochrane	RR 0.81 [0.63, 1.03]	33 studies · 6187 participants	Very low
Calcium supplementation/fortification vs control Adverse events (secondary outcome) · People who may be at risk for primary hypertension Calcium supplementation for prevention of primary hypertension (2022) · Cochrane	no estimate extracted	NR	No studies

Reviews 56

Effect of alcohol on blood pressure

Tasnim, S, Tang, C, et al. · Cochrane Database of Systematic Reviews · 2020

Hypertension

Thinnest evidence

Reviews 56

Effect of alcohol on blood pressure

Pharmacotherapy for hypertension in adults 60 years or older

First‐line drugs for hypertension

First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension

Acupuncture for hypertension

Fluvastatin for lowering lipids

Beta‐blockers for hypertension

Blood pressure lowering efficacy of renin inhibitors for primary hypertension

Pharmacotherapy for hypertension in adults aged 18 to 59 years

Effect of cocoa on blood pressure

Eplerenone for hypertension

Blood pressure targets for hypertension in older adults

Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension

Blood pressure lowering efficacy of beta‐1 selective beta blockers for primary hypertension

Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals

Blood pressure‐lowering efficacy of loop diuretics for primary hypertension

Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension

Atorvastatin for lowering lipids

Blood pressure‐lowering efficacy of monotherapy with thiazide diuretics for primary hypertension

Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension

Blood pressure lowering efficacy of nonselective beta‐blockers for primary hypertension

Pharmacological interventions for hypertension in children

Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension

Time course for blood pressure lowering of dihydropyridine calcium channel blockers

Rosuvastatin for lowering lipids